A Phase 1b Safety Study of Abiraterone Acetate (JNJ-212082) and Docetaxel in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Phase of Trial: Phase I
Latest Information Update: 12 Jun 2017
At a glance
- Drugs Abiraterone acetate (Primary) ; Docetaxel; Prednisone
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors Cougar Biotechnology
- 10 Jun 2017 Biomarkers information updated
- 07 Jun 2017 Status changed from active, no longer recruiting to completed.
- 20 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Feb 2017.